3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasm Metastasis
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Clear-cell metastatic renal cell carcinoma
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
21
Nivolumab
7
Docetaxel
7
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Trastuzumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
atezolizumab
3
Taxes
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Counseling
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
poly ICLC
2
durvalumab
2
belinostat
2
X-Rays
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
lenvatinib
×
Genitourinary
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled